Skip to Content
MedicinaMedicina
  • Article
  • Open Access

18 November 2026

11 Pages

Competing Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity

,
,
and
1
Department of General Surgery, Akdeniz University Faculty of Medicine, Antalya 07070, Türkiye
2
Department of Radiology, Akdeniz University Faculty of Medicine, Antalya 07070, Türkiye
*
Author to whom correspondence should be addressed.
This article belongs to the Section Oncology

Abstract

Background and Objectives: Adenoid cystic carcinoma of the breast is a rare special-type tumor that is characteristically triple-negative yet behaves indolently, unlike conventional triple-negative disease. How its mortality is divided between the cancer itself and competing causes, and how that balance changes with age, has not been characterized in a contemporary population-based cohort. Materials and Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER-17, 2000–2023), we identified women with primary breast adenoid cystic carcinoma (ICD-O-3 8200/3). After restriction to first or only malignant primaries and exclusion of metastatic disease, 917 patients were analyzed. Breast cancer-specific survival (BCSS) and overall survival were estimated by Kaplan–Meier; competing-risk cumulative incidence (breast cancer vs. other-cause death) was estimated by the Aalen–Johansen estimator, overall and by age, with differences across age groups tested. Determinants of breast cancer death were modeled with cause-specific Cox regression restricted to patients with known grade. Results: The median age was 62 years; of the whole cohort, 81.4% of tumors were localized and 3.5% were node-positive, and 75.6% of classifiable cases were triple-negative. BCSS was 95.9%, 93.3%, and 91.2% at 5, 10, and 15 years. Although 205 women (22.4%) died, only 53 (5.8%) died of breast cancer; the 15-year cumulative incidence of non-cancer death (24.0%) was threefold that of breast cancer death (8.1%) and approximated the expected background mortality for this age. Breast cancer death did not differ across age groups, whereas other-cause death rose steeply with age: at 10 years, it reached 39% versus 7% for cancer in women aged ≥ 70, in whom only 13% of all deaths were cancer-related. Among patients with known grade, node positivity (hazard ratio 8.40) and high grade (2.42) predicted breast cancer death, whereas age did not. The competing-mortality structure was unchanged in the documented triple-negative subset. Conclusions: Breast adenoid cystic carcinoma is a predominantly triple-negative but indolent malignancy in which competing, non-cancer mortality dominates the clinical course, overwhelmingly so in older women, and breast cancer death is largely confined to high-grade, node-positive tumors. These findings favor individualized, age-adapted management rather than routine escalation based on the triple-negative label alone.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.